Forecast

There is no analyst data available for this company.

News Go to news feed

Ascletis launches global phase‑III trials for oral obesity drug ASC30

Ascletis has launched a global phase‑III program for the oral GLP‑1 agent ASC30, comprising the approval‑relevant studies AURORA‑1 (without type‑2 diabetes) and AURORA‑2 (with type‑2 diabetes) with about 4,600 participants in the US, Europe and Canada. Both randomized, double‑blind, placebo‑controlled studies test three maintenance doses (20/40/60 mg daily) over 72 weeks; topline data are expected in Q3 2028. Ascletis plans an FDA filing by the end of 2028 and an EMA filing in early 2029, and also reported preclinical data for an oral triple agonist showing up to 15.2% weight reduction in primates. The company says it has sufficient liquidity through 2029 and is pursuing a portfolio of five oral candidates with further IND plans for 2026. » More on de.investing.com
Ascletis presents positive preclinical data for once-monthly obesity injection

Ascletis will present preclinical data for ASC36_35 FDC at the EASD annual meeting, a once-monthly subcutaneously administered combination of amylin receptor and GLP-1R/GIPR agonists. In a diet-induced obesity animal model, the fixed-dose combination showed superior weight loss compared with the Eloralintid/Tirzepatid combination. The candidate uses Ascletis' "Self-Assembling Lipid Depot" formulation on the Ultra-Long-Acting Platform and could, according to the CEO, enable greater weight losses in humans. » More on de.investing.com
Sagimet: acne drug Denifanstat meets all endpoints in phase‑3 study

Sagimet reports that the FASN inhibitor Denifanstat met all primary and secondary endpoints and was well tolerated in a randomized phase‑3 study conducted by Ascletis in China. Versus placebo, Denifanstat showed a placebo‑adjusted increase in treatment success rate of 18.6%, a reduction in total lesions of 22.0%, and a decrease in inflammatory lesions of 20.2%. Sagimet is advancing approval efforts in China, developing TVB‑3567 as a second FASN inhibitor, and holds FDA Breakthrough‑Therapy status for Denifanstat for MASH outside China. The company also announced a change of external auditor to KPMG and a sales agreement for up to $75 million of stock via an at‑the‑market program; analyst targets range from $11 to $33. » More on de.investing.com

Financials

In the last quarter, Ascletis Pharma had revenue of 115,37k€ and net profit of −33,13M€

(EUR)	Dec 2025	YoY
Revenue	+115,37k	-
Gross profit	+49,46k	-
Net profit	−33,13M	-
EBITDA	−35,08M	-

Fundamentals

Metric	Value
Market capitalization	+1,19Mld€
Number of shares	1,05Mld
52-week high/low	+2,17€ - +0,87€
Dividends	No
Beta	0,38
P/E ratio	−23,96
PEG ratio	+0,69
P/B ratio	+4,52
P/S ratio	+4.599,03

Company profile

Ascletis Pharma Inc. ist ein Biotechnologieunternehmen, das sich mit der Erforschung und Entwicklung, der Herstellung, dem Marketing und dem Verkauf von pharmazeutischen Produkten in Festlandchina und international beschäftigt. Das Unternehmen bietet Ritonavir in Tablettenform an, einen pharmakokinetischen Booster für verschiedene orale antivirale Medikamente, die auf virale Proteasen abzielen, und einen Bestandteil des zugelassenen oralen antiviralen Medikaments Paxlovid; ASCLEVIR und GANOVO für die Behandlung des Hepatitis-C-Virus. Das Unternehmen entwickelt außerdem ASC22 zur Behandlung von chronischer Hepatitis B (CHB) und zur funktionellen Heilung des menschlichen Immunschwächevirus; ASC42 zur funktionellen Heilung von chronischer Hepatitis B; ASC10 und ASC11 zur Behandlung von COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC und ASC45F FDC zur Behandlung von nicht-alkoholischer Steatohepatitis; und ASC42 zur Behandlung von primärer biliärer Cholangitis. Darüber hinaus entwickelt das Unternehmen ASC40 zur Behandlung von rezidivierendem Glioblastom, arzneimittelresistentem Brustkrebs und nicht-kleinzelligem Lungenkrebs mit KRAS-Mutation, ASC61 und ASC63 für fortgeschrittene solide Tumore, ASC60 zur Behandlung solider Tumore und ASC40 zur Behandlung von Akne. Ascletis Pharma Inc. wurde 2013 gegründet und hat seinen Hauptsitz in Hangzhou, Volksrepublik China.